Outcomes of four patients with homocysteine remethylation disorders detected by newborn screening

Derek Wong, Silvia Tortorelli, Lisa Bishop, Elizabeth A. Sellars, Lisa A. Schimmenti, Natalie Gallant, Carlos E. Prada, Robert J. Hopkin, Nancy D. Leslie, Susan A. Berry, David S. Rosenblatt, Amy L. Fair, Dietrich Matern, Kimiyo Raymond, Devin Oglesbee, Piero Rinaldo, Dimitar Gavrilov

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Purpose:We evaluated the clinical outcome in homocysteine remethylation disorders following newborn screening (NBS) and initiation of early specific treatment.Methods:Five patients with remethylation disorders were included in this study.Results:Two asymptomatic patients (one with cblG and one with cblE) were identified by NBS using an approach that combines a postanalytical interpretive tool (available on the Region 4 Stork (R4S) collaborative project website, http://www.clir-r4s.org) and a second-tier test for total homocysteine determination. Both the initial screening and the second-tier test are performed on the same blood spot, with no additional patient contact, resulting in no false-positive outcomes. Two additional patients with methylenetetrahydrofolate reductase deficiency were detected by NBS using low methionine as a marker. Although already symptomatic despite the early diagnosis, the latter two patients greatly improved with treatment and their outcomes are compared with that of another patient with methylenetetrahydrofolate reductase deficiency and significant morbidity who was diagnosed clinically at 3 months of age.Conclusion:Early detection by NBS and timely and specific treatment considerably improve at least short-term outcomes of homocysteine remethylation disorders. When a remethylation disorder is suspected, group-specific treatment could be started prior to the completion of in vitro confirmatory testing because all disorders from this group require similar intervention.

Original languageEnglish (US)
Pages (from-to)162-167
Number of pages6
JournalGenetics in Medicine
Volume18
Issue number2
DOIs
StatePublished - Feb 1 2016

Fingerprint

Homocysteine
Newborn Infant
Methionine
Early Diagnosis
Therapeutics
Morbidity

Keywords

  • homocysteine
  • newborn screening
  • Region 4 Stork tool
  • Remethylation disorders
  • second-tier testing

ASJC Scopus subject areas

  • Genetics(clinical)

Cite this

Wong, D., Tortorelli, S., Bishop, L., Sellars, E. A., Schimmenti, L. A., Gallant, N., ... Gavrilov, D. (2016). Outcomes of four patients with homocysteine remethylation disorders detected by newborn screening. Genetics in Medicine, 18(2), 162-167. https://doi.org/10.1038/gim.2015.45

Outcomes of four patients with homocysteine remethylation disorders detected by newborn screening. / Wong, Derek; Tortorelli, Silvia; Bishop, Lisa; Sellars, Elizabeth A.; Schimmenti, Lisa A.; Gallant, Natalie; Prada, Carlos E.; Hopkin, Robert J.; Leslie, Nancy D.; Berry, Susan A.; Rosenblatt, David S.; Fair, Amy L.; Matern, Dietrich; Raymond, Kimiyo; Oglesbee, Devin; Rinaldo, Piero; Gavrilov, Dimitar.

In: Genetics in Medicine, Vol. 18, No. 2, 01.02.2016, p. 162-167.

Research output: Contribution to journalArticle

Wong, D, Tortorelli, S, Bishop, L, Sellars, EA, Schimmenti, LA, Gallant, N, Prada, CE, Hopkin, RJ, Leslie, ND, Berry, SA, Rosenblatt, DS, Fair, AL, Matern, D, Raymond, K, Oglesbee, D, Rinaldo, P & Gavrilov, D 2016, 'Outcomes of four patients with homocysteine remethylation disorders detected by newborn screening', Genetics in Medicine, vol. 18, no. 2, pp. 162-167. https://doi.org/10.1038/gim.2015.45
Wong D, Tortorelli S, Bishop L, Sellars EA, Schimmenti LA, Gallant N et al. Outcomes of four patients with homocysteine remethylation disorders detected by newborn screening. Genetics in Medicine. 2016 Feb 1;18(2):162-167. https://doi.org/10.1038/gim.2015.45
Wong, Derek ; Tortorelli, Silvia ; Bishop, Lisa ; Sellars, Elizabeth A. ; Schimmenti, Lisa A. ; Gallant, Natalie ; Prada, Carlos E. ; Hopkin, Robert J. ; Leslie, Nancy D. ; Berry, Susan A. ; Rosenblatt, David S. ; Fair, Amy L. ; Matern, Dietrich ; Raymond, Kimiyo ; Oglesbee, Devin ; Rinaldo, Piero ; Gavrilov, Dimitar. / Outcomes of four patients with homocysteine remethylation disorders detected by newborn screening. In: Genetics in Medicine. 2016 ; Vol. 18, No. 2. pp. 162-167.
@article{8551e57ba9b944e9aeb4c4076a2a43a0,
title = "Outcomes of four patients with homocysteine remethylation disorders detected by newborn screening",
abstract = "Purpose:We evaluated the clinical outcome in homocysteine remethylation disorders following newborn screening (NBS) and initiation of early specific treatment.Methods:Five patients with remethylation disorders were included in this study.Results:Two asymptomatic patients (one with cblG and one with cblE) were identified by NBS using an approach that combines a postanalytical interpretive tool (available on the Region 4 Stork (R4S) collaborative project website, http://www.clir-r4s.org) and a second-tier test for total homocysteine determination. Both the initial screening and the second-tier test are performed on the same blood spot, with no additional patient contact, resulting in no false-positive outcomes. Two additional patients with methylenetetrahydrofolate reductase deficiency were detected by NBS using low methionine as a marker. Although already symptomatic despite the early diagnosis, the latter two patients greatly improved with treatment and their outcomes are compared with that of another patient with methylenetetrahydrofolate reductase deficiency and significant morbidity who was diagnosed clinically at 3 months of age.Conclusion:Early detection by NBS and timely and specific treatment considerably improve at least short-term outcomes of homocysteine remethylation disorders. When a remethylation disorder is suspected, group-specific treatment could be started prior to the completion of in vitro confirmatory testing because all disorders from this group require similar intervention.",
keywords = "homocysteine, newborn screening, Region 4 Stork tool, Remethylation disorders, second-tier testing",
author = "Derek Wong and Silvia Tortorelli and Lisa Bishop and Sellars, {Elizabeth A.} and Schimmenti, {Lisa A.} and Natalie Gallant and Prada, {Carlos E.} and Hopkin, {Robert J.} and Leslie, {Nancy D.} and Berry, {Susan A.} and Rosenblatt, {David S.} and Fair, {Amy L.} and Dietrich Matern and Kimiyo Raymond and Devin Oglesbee and Piero Rinaldo and Dimitar Gavrilov",
year = "2016",
month = "2",
day = "1",
doi = "10.1038/gim.2015.45",
language = "English (US)",
volume = "18",
pages = "162--167",
journal = "Genetics in Medicine",
issn = "1098-3600",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Outcomes of four patients with homocysteine remethylation disorders detected by newborn screening

AU - Wong, Derek

AU - Tortorelli, Silvia

AU - Bishop, Lisa

AU - Sellars, Elizabeth A.

AU - Schimmenti, Lisa A.

AU - Gallant, Natalie

AU - Prada, Carlos E.

AU - Hopkin, Robert J.

AU - Leslie, Nancy D.

AU - Berry, Susan A.

AU - Rosenblatt, David S.

AU - Fair, Amy L.

AU - Matern, Dietrich

AU - Raymond, Kimiyo

AU - Oglesbee, Devin

AU - Rinaldo, Piero

AU - Gavrilov, Dimitar

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Purpose:We evaluated the clinical outcome in homocysteine remethylation disorders following newborn screening (NBS) and initiation of early specific treatment.Methods:Five patients with remethylation disorders were included in this study.Results:Two asymptomatic patients (one with cblG and one with cblE) were identified by NBS using an approach that combines a postanalytical interpretive tool (available on the Region 4 Stork (R4S) collaborative project website, http://www.clir-r4s.org) and a second-tier test for total homocysteine determination. Both the initial screening and the second-tier test are performed on the same blood spot, with no additional patient contact, resulting in no false-positive outcomes. Two additional patients with methylenetetrahydrofolate reductase deficiency were detected by NBS using low methionine as a marker. Although already symptomatic despite the early diagnosis, the latter two patients greatly improved with treatment and their outcomes are compared with that of another patient with methylenetetrahydrofolate reductase deficiency and significant morbidity who was diagnosed clinically at 3 months of age.Conclusion:Early detection by NBS and timely and specific treatment considerably improve at least short-term outcomes of homocysteine remethylation disorders. When a remethylation disorder is suspected, group-specific treatment could be started prior to the completion of in vitro confirmatory testing because all disorders from this group require similar intervention.

AB - Purpose:We evaluated the clinical outcome in homocysteine remethylation disorders following newborn screening (NBS) and initiation of early specific treatment.Methods:Five patients with remethylation disorders were included in this study.Results:Two asymptomatic patients (one with cblG and one with cblE) were identified by NBS using an approach that combines a postanalytical interpretive tool (available on the Region 4 Stork (R4S) collaborative project website, http://www.clir-r4s.org) and a second-tier test for total homocysteine determination. Both the initial screening and the second-tier test are performed on the same blood spot, with no additional patient contact, resulting in no false-positive outcomes. Two additional patients with methylenetetrahydrofolate reductase deficiency were detected by NBS using low methionine as a marker. Although already symptomatic despite the early diagnosis, the latter two patients greatly improved with treatment and their outcomes are compared with that of another patient with methylenetetrahydrofolate reductase deficiency and significant morbidity who was diagnosed clinically at 3 months of age.Conclusion:Early detection by NBS and timely and specific treatment considerably improve at least short-term outcomes of homocysteine remethylation disorders. When a remethylation disorder is suspected, group-specific treatment could be started prior to the completion of in vitro confirmatory testing because all disorders from this group require similar intervention.

KW - homocysteine

KW - newborn screening

KW - Region 4 Stork tool

KW - Remethylation disorders

KW - second-tier testing

UR - http://www.scopus.com/inward/record.url?scp=84957666956&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957666956&partnerID=8YFLogxK

U2 - 10.1038/gim.2015.45

DO - 10.1038/gim.2015.45

M3 - Article

C2 - 25856670

AN - SCOPUS:84957666956

VL - 18

SP - 162

EP - 167

JO - Genetics in Medicine

JF - Genetics in Medicine

SN - 1098-3600

IS - 2

ER -